Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.

three capitals of granite columns displayed in a shop canteria - Image
Array's assets align with Pfizer's three oncology strategy pillars. • Source: Shutterstock

The three main value drivers behind Pfizer Inc.'s $11.4bn purchase of Array BioPharma Inc. appear to align well with the three pillars the big pharma recently outlined for its mid- to long-term strategy in oncology, with Array's BRAF/MEK inhibitor combination Braftovi/Mektovi immediately contributing a small, but growing source of new revenue.

The deal announced on 17 June "makes sense to us as Pfizer works to further boost its innovative core," Credit...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.